Results 191 to 200 of about 2,671,764 (310)

Randomized Trials Meet Real-World Evidence in the Era of Combination CKD Therapies. [PDF]

Kidney Int Rep
Pecoits-Filho R, Bauer AC.
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

WCN25-52 EPIDEMIOLOGY OF IMMUNOGLOBULIN A NEPHROPATHY (IgAN) AND OCCURRENCE OF PROTEINURIA IN CHINA: EVIDENCE FROM SYSTEMATIC REVIEW AND META-ANALYSIS

Kidney International Reports
Zhaoxin Chen, Yilong Zhang, Wentian Lu, Jiaqi Kou, Jiaxi Zhu, Hema K. Gandhi, Sasikiran Nunna   +6 more
doaj   +1 more source

Use of Real-World Evidence in Health Technology Assessments of Non-Oncology Rare Disease Therapies. [PDF]

J Mark Access Health Policy
Blandy O, Lembo P, Folorunso R, Myren KJ, Chevrou-Severac H, Thomas SK.   +5 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

A Cross-Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real-World Evidence. [PDF]

Pharmacoepidemiol Drug Saf
Melinder M, Windfuhr F, Dahlqvist T, Torre C, Sepodes B, Mol PGM, Almeida D, Ekheden I, Feltelius N, Roes K, de Vries ST, Wettermark B.   +11 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Prognostic Value of p53 Status in Endometrial Cancer: Real-World Evidence from a Tertiary Center. [PDF]

Cancers (Basel)
Suprasert P, Salakphet T, Pongsuvareeyakul T, Khunamornpong S.   +3 more
europepmc   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Strengthening evidence-based medicine with real-world evidence

The Lancet Healthy Longevity, 2022
openaire   +2 more sources